Literature DB >> 30123873

Beware of broad-spectrum generalizations: ceftazidime-avibactam compared to meropenem for the treatment of gram-negative pneumonia.

Monica Mehta1, Anne-Catrin Uhlemann2.   

Abstract

Entities:  

Year:  2018        PMID： 30123873      PMCID： PMC6097712          DOI： 10.21037/jeccm.2018.05.02

Source DB:  PubMed          Journal:  J Emerg Crit Care Med        ISSN： 2521-3563


× No keyword cloud information.
  11 in total

1.  Population Structure of Klebsiella pneumoniae Causing Bloodstream Infections at a New York City Tertiary Care Hospital: Diversification of Multidrug-Resistant Isolates.

Authors:  Angela Gomez-Simmonds; Michelle Greenman; Sean B Sullivan; Joshua P Tanner; Madeleine G Sowash; Susan Whittier; Anne-Catrin Uhlemann
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

Review 2.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

3.  Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.

Authors:  Sutep Jaruratanasirikul; Suriyan Thengyai; Wibul Wongpoowarak; Thitima Wattanavijitkul; Kanyawisa Tangkitwanitjaroen; Waroonrat Sukarnjanaset; Monchana Jullangkoon; Maseetoh Samaeng
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

4.  In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.

Authors:  Paolo Gaibani; Caterina Campoli; Russell E Lewis; Silvia Lidia Volpe; Erika Scaltriti; Maddalena Giannella; Stefano Pongolini; Andrea Berlingeri; Francesco Cristini; Michele Bartoletti; Sara Tedeschi; Simone Ambretti
Journal:  J Antimicrob Chemother       Date:  2018-06-01       Impact factor: 5.790

5.  Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.

Authors:  Antoni Torres; Nanshan Zhong; Jan Pachl; Jean-François Timsit; Marin Kollef; Zhangjing Chen; Jie Song; Dianna Taylor; Peter J Laud; Gregory G Stone; Joseph W Chow
Journal:  Lancet Infect Dis       Date:  2017-12-16       Impact factor: 25.071

6.  Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Brian A Potoski; Rachel V Marini; Yohei Doi; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.

Authors:  Marla J Giddins; Nenad Macesic; Medini K Annavajhala; Stephania Stump; Sabrina Khan; Thomas H McConville; Monica Mehta; Angela Gomez-Simmonds; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 9.  Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.

Authors:  Marco Falcone; Pierluigi Viale; Giusy Tiseo; Manjunath Pai
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-01-31       Impact factor: 4.481

10.  Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Authors:  David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079
View more
  1 in total

Review 1.  Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria.

Authors:  Richard R Watkins; David Van Duin
Journal:  F1000Res       Date:  2019-01-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.